Short- and long-term increased risk of all-cause mortality in a tuberculosis cohort attributed to SARS-CoV-2 infection: a time-dependent survival analysis in Chile
| dc.article.number | 101119 | |
| dc.catalogador | gjm | |
| dc.contributor.author | Vargas García, Salvador | |
| dc.contributor.author | Undurraga, Eduardo A. | |
| dc.contributor.author | Escobar, Nadia | |
| dc.contributor.author | García, Christian | |
| dc.contributor.author | Vergara, Natalia | |
| dc.contributor.author | Balcells Marty, María Elvira | |
| dc.date.accessioned | 2025-05-22T13:59:13Z | |
| dc.date.available | 2025-05-22T13:59:13Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | Background: Concurrent tuberculosis (TB) and COVID-19 increases the risk of mortality; however, most studies have focused primarily on short-term outcomes. We assessed the short and long-term impact of TB and SARS-CoV-2 coinfection on all-cause mortality. Methods: We conducted a retrospective nationwide cohort study in Chile, including adults diagnosed with active TB from January 1st, 2020, to December 31st, 2021, with follow-up until November 30th, 2022. SARS-CoV-2 coinfection was defined as occurring from 30 days before to six months after TB diagnosis. Short-term mortality was defined as death within 90 days of TB or TB/SARS-CoV-2 diagnosis, and long-term mortality as death occurring after 90 days. We used a time-dependent Cox survival analysis, adjusting for sociodemographic factors, SARS-CoV-2 vaccination, and relevant comorbidities including HIV, diabetes and Mycobacterium tuberculosis drug-resistance status. Findings: The cohort included 3721 adults (median age: 47 years, interquartile range [IQR]: 32–61); of whom 63·4% were male, and 79·4% had pulmonary TB. The median follow-up was 586 days (IQR: 401–820), with 680 deaths (18·3%) recorded. A SARS-CoV-2 coinfection was identified in 393 individuals (10·5%); the mortality in this group was higher in short-term (≤90 days: 14·5% vs. 11·4%) and long-term (>90 days: 11·5% vs. 5·9%) compared to TB alone. Coinfection increased the risk of all-cause mortality during the entire follow-up (aHR [adjusted Hazard Ratio]: 2·8, 95% CI: 2·26–3·47), over three-fold in the short-term (aHR 3·4, 95% CI: 2·57–4·51) and nearly two-fold in the long-term (aHR: 1·72, 95% CI: 1·18–2·52). Excess mortality persisted beyond the first year (aHR: 2·04, 95% CI: 1·09–3·82). SARS-CoV-2 vaccination reduced mortality risk in the TB cohort by 35% (95% CI: 19–46%). Interpretation: Tuberculosis and SARS-CoV-2 coinfection was associated with significantly increased all-cause mortality in both the short and long-term, with elevated risk persisting beyond TB treatment completion. These findings highlight the need for continued post-treatment follow-up and prioritization of SARS-CoV-2 vaccination among individuals with TB. | |
| dc.format.extent | 13 páginas | |
| dc.fuente.origen | ORCID | |
| dc.identifier.doi | 10.1016/j.lana.2025.101119 | |
| dc.identifier.uri | https://doi.org/10.1016/j.lana.2025.101119 | |
| dc.identifier.uri | https://repositorio.uc.cl/handle/11534/104427 | |
| dc.information.autoruc | Escuela de Medicina; Vargas García, Salvador; S/I; 1186484 | |
| dc.information.autoruc | Escuela de Gobierno; Undurraga Fourcade, Eduardo Andrés; 0000-0002-4425-1253; 12868 | |
| dc.information.autoruc | Escuela de Medicina; Balcells Marty, María Elvira; 0000-0002-7223-9665; 7462 | |
| dc.language.iso | en | |
| dc.nota.acceso | contenido completo | |
| dc.revista | The Lancet Regional Health - Americas | |
| dc.rights | acceso abierto | |
| dc.rights.license | CC BY-NC-ND 4.0 Attribution-NonCommercial-NoDerivatives 4.0 International | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Mycobacterium tuberculosis | |
| dc.subject | Tuberculosis | |
| dc.subject | COVID-19 | |
| dc.subject | SARS-CoV-2 | |
| dc.subject | Global health | |
| dc.subject | Cohort | |
| dc.subject | Chile | |
| dc.subject.ddc | 610 | |
| dc.subject.dewey | Medicina y salud | es_ES |
| dc.title | Short- and long-term increased risk of all-cause mortality in a tuberculosis cohort attributed to SARS-CoV-2 infection: a time-dependent survival analysis in Chile | |
| dc.type | artículo | |
| dc.volumen | 46 | |
| sipa.codpersvinculados | 1186484 | |
| sipa.codpersvinculados | 12868 | |
| sipa.codpersvinculados | 7462 | |
| sipa.trazabilidad | ORCID;2025-05-19 |
